company background image
MGNX logo

MacroGenics NasdaqGS:MGNX Voorraadrapport

Laatste prijs

US$3.87

Marktkapitalisatie

US$242.7m

7D

9.9%

1Y

-28.9%

Bijgewerkt

04 Nov, 2024

Gegevens

Financiële gegevens bedrijf +

MacroGenics, Inc.

NasdaqGS:MGNX Voorraadrapport

Marktkapitalisatie: US$242.7m

MGNX Overzicht aandelen

MacroGenics, Inc., een biofarmaceutisch bedrijf, ontwikkelt, produceert en verkoopt therapeutica op basis van antilichamen voor de behandeling van kanker in de Verenigde Staten.

MacroGenics, Inc. Concurrenten

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor MacroGenics
Historische aandelenkoersen
Huidige aandelenkoersUS$3.87
52 Week HoogtepuntUS$21.88
52 Week LaagUS$2.95
Bèta2.07
11 maand verandering7.80%
3 maanden verandering6.32%
1 Jaar Verandering-28.86%
33 jaar verandering-81.42%
5 jaar verandering-51.29%
Verandering sinds IPO-84.51%

Recent nieuws en updates

Party Time: Brokers Just Made Major Increases To Their MacroGenics, Inc. (NASDAQ:MGNX) Earnings Forecasts

Aug 01
Party Time: Brokers Just Made Major Increases To Their MacroGenics, Inc. (NASDAQ:MGNX) Earnings Forecasts

Recent updates

Party Time: Brokers Just Made Major Increases To Their MacroGenics, Inc. (NASDAQ:MGNX) Earnings Forecasts

Aug 01
Party Time: Brokers Just Made Major Increases To Their MacroGenics, Inc. (NASDAQ:MGNX) Earnings Forecasts

MacroGenics, Inc.'s (NASDAQ:MGNX) Share Price Boosted 29% But Its Business Prospects Need A Lift Too

Jul 30
MacroGenics, Inc.'s (NASDAQ:MGNX) Share Price Boosted 29% But Its Business Prospects Need A Lift Too

We're A Little Worried About MacroGenics' (NASDAQ:MGNX) Cash Burn Rate

Jul 12
We're A Little Worried About MacroGenics' (NASDAQ:MGNX) Cash Burn Rate

MacroGenics, Inc.'s (NASDAQ:MGNX) 81% Dip In Price Shows Sentiment Is Matching Revenues

May 13
MacroGenics, Inc.'s (NASDAQ:MGNX) 81% Dip In Price Shows Sentiment Is Matching Revenues

MacroGenics: Strong Likelihood Bad News Has Caused Overreaction (Rating Upgrade)

May 13

MacroGenics: Positive Safety Update Leads To Two Major Inflection Points In 2024

Apr 05

MacroGenics, Inc. (NASDAQ:MGNX) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Feb 28
MacroGenics, Inc. (NASDAQ:MGNX) Surges 27% Yet Its Low P/S Is No Reason For Excitement

MacroGenics: Trying To Build A Better Everything

Feb 15

There's No Escaping MacroGenics, Inc.'s (NASDAQ:MGNX) Muted Revenues

Jan 09
There's No Escaping MacroGenics, Inc.'s (NASDAQ:MGNX) Muted Revenues

Benign Growth For MacroGenics, Inc. (NASDAQ:MGNX) Underpins Its Share Price

May 17
Benign Growth For MacroGenics, Inc. (NASDAQ:MGNX) Underpins Its Share Price

Analyst Forecasts For MacroGenics, Inc. (NASDAQ:MGNX) Are Surging Higher

Mar 11
Analyst Forecasts For MacroGenics, Inc. (NASDAQ:MGNX) Are Surging Higher

Here's Why MacroGenics (NASDAQ:MGNX) Must Use Its Cash Wisely

Jan 25
Here's Why MacroGenics (NASDAQ:MGNX) Must Use Its Cash Wisely

Analysts' Revenue Estimates For MacroGenics, Inc. (NASDAQ:MGNX) Are Surging Higher

Oct 25
Analysts' Revenue Estimates For MacroGenics, Inc. (NASDAQ:MGNX) Are Surging Higher

MacroGenics: No Near-Term Catalysts

Oct 11

Israel Englander and his Millennium fund disclose 5.2% passive stake in MacroGenics

Sep 02

MacroGenics Q2 2022 Earnings Preview

Aug 05

Companies Like MacroGenics (NASDAQ:MGNX) Could Be Quite Risky

Jul 25
Companies Like MacroGenics (NASDAQ:MGNX) Could Be Quite Risky

MacroGenics halts mid-stage head and neck cancer study after fatalities

Jul 11

The Consensus EPS Estimates For MacroGenics, Inc. (NASDAQ:MGNX) Just Fell Dramatically

May 09
The Consensus EPS Estimates For MacroGenics, Inc. (NASDAQ:MGNX) Just Fell Dramatically

We're Keeping An Eye On MacroGenics' (NASDAQ:MGNX) Cash Burn Rate

Apr 12
We're Keeping An Eye On MacroGenics' (NASDAQ:MGNX) Cash Burn Rate

Rendement voor aandeelhouders

MGNXUS BiotechsUS Markt
7D9.9%-0.7%-1.6%
1Y-28.9%19.8%30.8%

Rendement versus industrie: MGNX underperformed the US Biotechs industry which returned 19.8% over the past year.

Rendement versus markt: MGNX underperformed the US Market which returned 30.8% over the past year.

Prijsvolatiliteit

Is MGNX's price volatile compared to industry and market?
MGNX volatility
MGNX Average Weekly Movement9.5%
Biotechs Industry Average Movement9.6%
Market Average Movement6.0%
10% most volatile stocks in US Market14.9%
10% least volatile stocks in US Market2.9%

Stabiele aandelenkoers: MGNX has not had significant price volatility in the past 3 months compared to the US market.

Volatiliteit in de loop van de tijd: MGNX's weekly volatility has decreased from 17% to 9% over the past year.

Over het bedrijf

OpgerichtWerknemersCEOWebsite
2000339Scott Koenigwww.macrogenics.com

MacroGenics, Inc, een biofarmaceutisch bedrijf, ontwikkelt, produceert en commercialiseert therapeutica op basis van antilichamen voor de behandeling van kanker in de Verenigde Staten. Zijn goedgekeurde product is MARGENZA (margetuximab-cmkb), een receptorantagonist tegen de humane epidermale groeifactor 2 (HER2) die, in combinatie met chemotherapie, is geïndiceerd voor de behandeling van volwassen patiënten met uitgezaaide HER2-positieve borstkanker die twee of meer voorafgaande anti-HER2-regimes hebben gekregen. De pijplijn van immuno-oncologische productkandidaten van het bedrijf omvat MGC018, een antibody drug conjugate (ADC), dat zich richt op solide tumoren die B7-H3 tot expressie brengen; Enoblituzumab, een monoklonaal antilichaam dat zich richt op B7-H3; en MGD024, een onderzocht bispecifiek CD123 × CD3 DART-molecuul om het cytokine-releasesyndroom te minimaliseren voor patiënten met hematologische maligniteiten.

MacroGenics, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van MacroGenics zich tot de beurswaarde?
MGNX fundamentele statistieken
MarktkapitalisatieUS$242.74m
Inkomsten(TTM)-US$136.37m
Inkomsten(TTM)US$41.02m

5.9x

P/S-verhouding

-1.8x

Koers/Winstverhouding

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
MGNX resultatenrekening (TTM)
InkomstenUS$41.02m
Kosten van inkomstenUS$176.48m
Brutowinst-US$135.46m
Overige uitgavenUS$914.00k
Inkomsten-US$136.37m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

Nov 05, 2024

Winst per aandeel (EPS)-2.17
Brutomarge-330.24%
Nettowinstmarge-332.47%
Schuld/Eigen Vermogen Verhouding0%

Hoe presteerde MGNX op de lange termijn?

Bekijk historische prestaties en vergelijking